Last reviewed · How we verify
TR-701 di-sodium phosphate salt — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TR-701 di-sodium phosphate salt (TR-701 di-sodium phosphate salt) — Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TR-701 di-sodium phosphate salt TARGET | TR-701 di-sodium phosphate salt | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TR-701 di-sodium phosphate salt CI watch — RSS
- TR-701 di-sodium phosphate salt CI watch — Atom
- TR-701 di-sodium phosphate salt CI watch — JSON
- TR-701 di-sodium phosphate salt alone — RSS
Cite this brief
Drug Landscape (2026). TR-701 di-sodium phosphate salt — Competitive Intelligence Brief. https://druglandscape.com/ci/tr-701-di-sodium-phosphate-salt. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab